BMO Capital raised the firm’s price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby’s U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook
- BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating
- BridgeBio presents data from ATTRibute-CM
- BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential
- BridgeBio announces first participant dosed with acoramidis in ACT-EARLY
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue